Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are now established first-line options for EGFR mutation positive non-small cell lung cancer (NSCLC). While the first (1G) ...
No takes yet. Share an insight, caveat, or question.
Tan et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: